Investing in AI, Semiconductors, Biotech, and Data Infrastructure in 2026: How Immigration, Trade, and CFIUS Shape Returns and Deal Certainty

Key Message:

Global investors in AI, machine learning, semiconductors, biotech, and data infrastructure face intersecting regulatory risks that affect talent, supply chains, governance, and exits. Those who integrate immigration, CFIUS, and trade strategy early gain a competitive advantage—mitigating risk while unlocking upside.

1. Talent Mobility: Continuity Is Regulatory as Well as Operational

Foreign-born founders and technical experts remain indispensable. But in 2026, immigration risk is more than hiring delays—it can affect CFIUS exposure, access to controlled technology, and deal certainty. U.S. Export Administration Regulations (EAR) impose “deemed export” rules, meaning that allowing foreign nationals access to controlled AI or machine-learning technology can itself constitute an export requiring regulatory clearance.

Case Hypothetical:

A U.S. AI startup has foreign national engineers on temporary visas. During a growth-round investment by a foreign fund, regulators evaluate not just ownership, but whether the engineers’ access to proprietary datasets triggers national security concerns. Delays in visa approval coincide with a funding milestone, impacting valuation.

Action for Investors:

• Map visa and access status for founders and technical leads.

• Assess single-point-of-failure risks.

• Align immigration planning with equity, board control, and succession.

2. Trade, Supply Chains, and Export Controls Are Now Core Diligence

Startups in semiconductors, biotech, and data centers rely on complex global supply chains. Tariff volatility, export controls, and industrial policy shifts affect both costs and regulatory exposure. Export control rules cover emerging and foundational technologies, including semiconductor designs and AI/ML software, and even technical assistance or collaborative projects with foreign partners can trigger compliance obligations under EAR.

Case Hypothetical:

A semiconductor startup sources chips overseas while designing IP in the U.S. New export control classifications and tariffs raise both cost and compliance risk during late-stage financing, affecting cash flow and investor confidence.

Investor Guidance:

• Map supply chains for export control and tariff exposure.

• Evaluate technical collaboration risks that could trigger deemed export concerns, including sharing software, designs, or training foreign engineers.

• Integrate trade compliance into valuation and exit planning.

3. CFIUS: Minority Investments and Access Can Trigger Review

CFIUS scrutiny now extends beyond full acquisitions. Under FIRRMA (the Foreign Investment Risk Review Modernization Act), even minority investments, board observer rights, or enhanced access to sensitive information can trigger review if the company is a “TID U.S. Business” handling technology, infrastructure, or sensitive data. This includes AI models, controlled biotech, or critical data systems.

Case Hypothetical:

A foreign fund invests in a biotech startup handling sensitive genomic data. No control rights are taken, but enhanced information rights combined with foreign national access prompt CFIUS review, delaying funding and complicating governance.

Investor Guidance:

• Evaluate data access and control structures.

• Align immigration and access policies with CFIUS compliance.

• Structure minority investments to limit review triggers.

4. Why Integrated Legal Strategy Creates Value

Immigration, CFIUS, and trade regulations increasingly stack inside the same company. Investors who address them holistically preserve optionality, accelerate funding, and maintain valuation. For example, an AI startup preparing for acquisition may have engineers working on export-controlled components; unresolved visa compliance plus potential CFIUS review can delay a closing and reduce leverage.

Investor Advantage:

• Integrated counsel aligns talent, data access, and investment structure.

• Anticipates regulatory scrutiny before it hits due diligence.

• Converts regulatory complexity into a value creation tool.

5. Actionable Takeaways for 2026 Investors

To compete and protect returns, global VC and PE firms should:

• Expand diligence to include talent mobility, access, and regulatory readiness, including EAR deemed export implications.

• Stress-test minority rights for CFIUS sensitivity in TID U.S. businesses.

• Evaluate supply chains through a trade and export-control lens, including technical assistance risks.

• Plan exits early, resolving immigration and CFIUS issues before liquidity events.

• Signal regulatory fluency to founders—it differentiates your capital from competitors.

Final Thought

In AI, semiconductors, biotech, and data infrastructure, regulatory fluency is a market signal. Investors who understand the interplay of immigration, trade, and national security regulations reduce execution risk, preserve optionality, and position themselves as trusted long-term partners. Navigating these intersections early is not just good lawyering—it is smart investing.

About the Author

Kripa Upadhyay is a recognized thought leader in cross-border investment and regulatory strategy. She has written extensively on FIRRMA, CFIUS, and export-control developments, offering insights on how talent mobility, data access, and supply chains affect deal certainty. Her research bridges law and investment strategy, helping investors anticipate regulatory challenges before they impact transactions.

This communication is not intended to create or constitute, nor does it create or constitute, an attorney-client or any other legal relationship. No statement in this communication constitutes legal advice nor should any communication herein be construed, relied upon, or interpreted as legal advice. This communication is for general information purposes only regarding recent legal developments of interest, and is not a substitute for legal counsel on any subject matter. No reader should act or refrain from acting on the basis of any information included herein without seeking appropriate legal advice on the particular facts and circumstances affecting that reader. For more information, visit www.buchalter.com.